

Table 2. Diagnostic profiles from studies comparing PET tracers and MIBG in Pheos/PGL

Published studies on PET agents vs. MIBG	Year	No. of patients	Disease type	PET sensitivity on patient - based analysis	PET sensitivity on lesion - based analysis	MIBG sensitivity on patient - based analysis	MIBG sensitivity on lesion - based analysis
¹¹C-HED							
Shulkin et al ⁵⁷	1992	10	Pheo	90%	NR	NR	NR
Franzius et al ⁵⁸	2006	7	Pheo/PGL	NR	100%	NR	90%
Mann et al ⁵⁹	2006	14	Pheo	100%	NR	50%	NR
¹⁸F-DA							
Ilias et al ⁴⁴	2003	16	Metastatic Pheo	100%	NR	56%	NR
Mamede et al ⁶⁰	2006	5	Metastatic Pheo	NR	NR	NR	NR
Kaji et al ⁴⁶	2007	7	VHL-related Pheo	100%	NR	57%	NR
Timmers et al ⁴⁷	2007	30	SDHB-related PGL	88%	NR	80%	NR
Ilias et al ⁵²	2008	53	Pheo	90%	NR	71%	NR
Zelinka et al ⁶¹	2008	71	Metastatic Pheo/PGL	90%	NR	71%	NR
Timmers et al ⁶²	2009	52	Metastatic/non-metastatic PGL	NR	76%/78%	NR	57%/78%
Timmers et al ⁶³	2009	99	Known or suspected PGL	92%	78% (non metastatic)	83%	78% (non metastatic)
King et al ⁴⁵	2011	10	SDHx-related H&N PGL	NR	46%	NR	31%
¹⁸F-DOPA							
Hoegerle et al ⁶⁴	2002	14	Pheo	NR	100%	NR	71%
Taieb et al ⁶⁵	2008	9	Malignant/multi-focal Pheo/PGL	100%	NR	75%	NR
Friebrich et al ⁶⁶	2009	48	Mainly Pheo	90%	73%	65%	48%
Timmers et al ⁶²	2009	52	Metastatic/non-metastatic PGL	NR	45%/81%	NR	57%/78%
Fottner et al ⁴³	2010	30	Pheo/PGL	96%	98%	80%	53%
Rufini et al ⁶⁷	2011	12	Recurrent malignant Pheo/PGL	100%	98%	75%	38%
King et al ⁴⁵	2011	10	SDHx-related H&N PGL	NR	100%	NR	31%
¹⁸F-FDG							
Shulkin et al ⁶⁸	1999	29	Pheo	76%	NR	86%	NR
Mann et al ⁵⁹	2006	14	Pheo	100%	NR	50%	NR
Mamede et al ⁶⁰	2006	5	Malignant/multi-focal Pheo/PGL	NR	NR	NR	NR
Timmers et al ⁴⁷	2007	30	SDHB-related PGL	100%	NR	80%	NR
Taieb et al ⁶⁵	2008	9	Malignant/multi-focal Pheo/PGL	89%	NR	75%	NR
Takano et al ⁶⁹	2008	11	Metastatic Pheo/PGL	100%	NR	82%	NR
Zelinka et al ⁶¹	2008	71	Metastatic Pheo/PGL	76%	NR	71%	NR
Timmers et al ⁶²	2009	52	Metastatic/non-metastatic PGL	NR	74%/88%	NR	57%/78%
King et al ⁴⁵	2011	10	SDHx-related H&N PGL	NR	77%	NR	31%
Timmers et al ⁷⁰	2012	216	Metastatic/non-metastatic PGL	NR	82%/77%	NR	50%/75%
Nakano et al ⁷¹	2012	8	Metastatic Pheo/PGL	NR	68%	87%	NR
⁶⁸Ga-peptides							
Win et al ⁷²	2007	5	Malignant Pheo	100%	NR	60%	NR
Kroiss et al ⁷³	2011	6	Metastatic Pheo	100%	92%	100%	63%
Naji et al ⁷⁴	2011	12	Pheo/PGL	83%	97%	42%	23%
Naswa et al ⁷⁵	2012	25	Pheo/PGL	100%	100%	NR	64%
Maurice et al ⁷⁶	2012	15	Pheo/PGL	87%	NR	67%	NR

¹¹C-HED: ¹¹C-hydroxyephedrine; ¹⁸F-DA: ¹⁸F-fluorodopamine; ¹⁸F-DOPA: ¹⁸F-dihydroxyphenylalanine; ¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose; NR: not reported